Free Newsletter
Teva seeks venture partner in Japan
Fresh off its $7.5 billion deal to buy Barr Pharmaceuticals, Teva is eyeing joint ventures in Japan. CEO Shlomo Yanai told the Financial Times that establishing a beachhead in that country is a top priority for him. Though Japan has historically stuck mostly to brand-name meds, partly because of quality concerns, Yanai believes that Teva's rep can overcome that reticence. "Right now Japan is more ripe for generics," he told the newspaper. "Japan is very important but difficult to break into."
Hence the desire for a joint venture, which would give Teva a foot in the door. That's not the only option, Yanai says, but it's "definitely the preferred option."
- see the Financial Times article
Relate darticles:
It's Teva plus Barr in a $7.46B buyout
Teva Pharmaceutical - best Pharma Stocks of 2007
Teva earmarks $1B for India
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: